Liver type 1 innate lymphoid cells undergo apoptosis in murine models of macrophage activation syndrome and are dispensable for disease
- PMID: 39348088
- DOI: 10.1002/eji.202451043
Liver type 1 innate lymphoid cells undergo apoptosis in murine models of macrophage activation syndrome and are dispensable for disease
Abstract
Macrophage activation syndrome (MAS) exemplifies a severe cytokine storm disorder with liver inflammation. In the liver, classical natural killer (cNK) cells and liver-resident type 1 innate lymphoid cells (ILC1s) dominate the ILC population. Thus far, research has primarily focused on the corresponding role of cNK cells. Considering the liver inflammation and cytokine storm in MAS, liver-resident ILC1s represent an interesting population to explore due to their rapid cytokine production upon environmental triggers. By utilizing a Toll-like receptor (TLR)9- and TLR3:4-triggered MAS model, we showed that ILC1s highly produce IFN-γ and TNF-α. However, activated ILC1s undergo apoptosis and are strongly reduced in numbers, while cNK cells resist inflammation-induced apoptosis. Signs of mitochondrial stress suggest that this ILC1 apoptosis may be driven by inflammation-induced mitochondrial impairment. To study whether early induction of highly cytokine-producing ILC1s influences MAS development, we used Hobit KO mice due to their paucity of liver ILC1s but unaffected cNK cell numbers. Nevertheless, neither the severity of MAS features nor the total inflammatory cytokine levels were affected in these Hobit KO mice, indicating that ILC1s are dispensable for MAS pathogenesis. Collectively, our data demonstrate that ILC1s undergo apoptosis during TLR-triggering and are dispensable for MAS pathogenesis.
Keywords: Apoptosis; Cytokine storm; Hobit knockout mice; Liver type 1 innate lymphoid cells; Macrophage activation syndrome.
© 2024 Wiley‐VCH GmbH.
References
-
- Weaver, L. K. and Behrens, E. M., Weathering the storm: Improving therapeutic interventions for cytokine storm syndromes by targeting disease pathogenesis. Curr. Treatm. Opt. Rheumatol. 2017. 3: 33–48.
-
- Ombrello, M. J. and Schulert, G. S., COVID‐19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome? Transl. Res. 2021. 232: 1–12.
-
- Vanderbeke, L., Van Mol, P., Van Herck, Y., De Smet, F., Humblet‐Baron, S., Martinod, K., Antoranz, A. et al., Monocyte‐driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID‐19 disease severity. Nat. Commun. 2021. 12: 4117.
-
- Billiau, A. D., Roskams, T., Van Damme‐Lombaerts, R., Matthys, P. and Wouters, C., Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN‐γ‐producing lymphocytes and IL‐6‐ and TNF‐α‐producing macrophages. Blood 2005. 105: 1648–1651.
-
- Grom, A. A., Horne, A. and De Benedetti, F., Macrophage activation syndrome in the era of biologic therapy. Nat. Rev. Rheumatol. 2016. 12: 259–268.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
